心脏病治疗学筹集了135万加元的资金,用于推进其心脏病药物CardiolRxTM。 Cardiol Therapeutics raises $13.5M in financing to advance its heart disease drug, CardiolRx™.

心脏病治疗公司宣布了一项购买交易融资,以筹集1 350万美元,出售1 040万个单位,每单位1.30美元,每个单位包括一个份额和半份许可证,在24个月内再以1.75美元购买另一个单位。 Cardiol Therapeutics Inc. announced a bought deal financing to raise $13.5 million, selling 10.4 million units at $1.30 each, with each unit including one share and half a warrant to buy another at $1.75 within 24 months. 承保人可能再购买10%的单位,可能再筹集135万美元。 The underwriter may purchase an additional 10% of units, potentially raising up to $1.35 million more. 这笔交易预计将于2026年1月23日结束,须经监管批准,并将资助研究、临床发展及其心脏病药物候选者CardiolRxTM的一般支出。 The deal, expected to close Jan. 23, 2026, is subject to regulatory approvals and will fund research, clinical development, and general expenses for its heart disease drug candidate, CardiolRx™. 这项提议豁免美国登记,加拿大合格投资者和美国某些投资者可享有豁免。 The offering is exempt from U.S. registration and available to qualified investors in Canada and certain U.S. investors under exemptions.